Protein C Inhibitor – PAI-3 Antibodies

Affinity Biologicals, Inc. manufactures a broad range of Protein C Inhibitor – PAI-3 Antibodies which can be found in the listing below.   Further information about each individual Protein C Inhibitor – PAI-3 Antibody is available by following the associated links.  Our Protein C Inhibitor – PAI-3 Antibodies are excellent for use in immunoassays where high sensitivity is required and are frequently the preferred reagent for immunopreciptaion techniques and activity neutralization assays.  These antibodies have proven to be extremely useful in the preparation of immune-adsorbent resins for use in immuno-depletion of specific proteins from plasma as well as immuno-affinity purification of proteins.  Affinity’s Protein C Inhibitor – PAI-3 Antibodies are manufactured for use in research applications.

Protein C Inhibitor, HumanHostCatalogue No.Size
Affinity Purified IgGGoatGAPCI-AP0.5mg vial
Peroxidase Conjugated IgGGoatGAPCI-HRP0.2mg vial
For EIA of Protein C InhibitorPCI-EIA5 plates
For EIA of APC-PCI ComplexAPCPCI-EIA5 plates

Listing of Protein C Inhibitor – PAI-3 Antibodies

Description of Protein C Inhibitor (PCI)

Protein C Inhibitor (PCI), also known as Plasminogen Activator Inhibitor 3 (PAI3), is a member of the SERPIN family of proteinase inhibitors. It is produced in the liver as a single chain glycoprotein (mass of 57 kDa) and circulates in plasma at a concentration of 5 μg/ml (~90 nM). PCI is also found in urine in lower concentrations of 250 ng/mL (~0.4 nM).  PCI is the primary inhibitor of activated Protein C (APC) in plasma but demonstrates a relatively broad specificity, also inhibiting thrombin, FXa, FXIa, kallikrein, tPA, urokinase, prostate specific antigen, acrosin, chymotrypsin and trypsin. The preferred enzyme target for PCI appears to be thrombin and this interaction is increased by more than 100 fold in the presence of thrombomodulin. Like ATIII and HCII, the inhibitory activity of PCI towards some of these enzymes is stimulated by high concentrations of heparin (5 U/ml) which can accelerate the rate of inactivation as much as 50 fold. Enzyme inhibition by PCI occurs through proteolytic cleavage at Arg354-Ser355 and subsequent rapid formation of a stable, inactive 1:1 enzyme-PCI complex. Interaction with APC results in an SDS-stable APC-PCI complex of 102 kDa.1-4.

References and Reivews

  1. Suzuki K; Protein C Inhibitor; Methods in Enzymology 222, pp 385-399, 1993.
  2. Cooper ST, Whinna HC, Jackson TP, Boyd JM, Church FC; Intermolecular Interactions between Protein C Inhibitor and Coagulation Proteases; Biochemistry: 34, pp. 12991-12997, 1995.
  3. Heeb MJ, Espana F, Geiger M, Collen D, Stump DC, Griffin JH; Immunological Identity of Heparin-dependent Plasma & Urinary Protein C Inhibitor & Plasminogen Activator Inhibitor-3; JBC:262, pp 15813-15816, 1987.
  4. Rezaie AR, Copper ST, Church FC, Esmon CT; Protein C Inhibitor is a Potent Inhibitor of the Thrombin-Thrombomodulin Complex; JBC:270, pp 25336-25339, 1995.